On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprine or 6-mercaptopurine intolerant IBD patients
| Autor: | P. M. Hooymans, A.B. Makelburg, L.P.L. Gilissen, S.Y. de Boer, N. K. H. de Boer, Luc J J Derijks, Cjj Mulder, G. den Hartog, Leopold G.J.B. Engels, Dirk J. de Jong, Daan W. Hommes, Anton H. Naber, B.D. Westerveld |
|---|---|
| Přispěvatelé: | Interne Geneeskunde, RS: NUTRIM School of Nutrition and Translational Research in Metabolism, VU University medical center, Faculteit der Geneeskunde |
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male medicine.medical_specialty Azathioprine Inflammatory bowel disease Gastroenterology Maintenance therapy Internal medicine medicine Humans Thioguanine Aged Retrospective Studies Chronic inflammation and autoimmunity [UMCN 4.2] Crohn's disease Mercaptopurine business.industry Drug Tolerance General Medicine Middle Aged Inflammatory Bowel Diseases medicine.disease Ulcerative colitis digestive system diseases Surgery Discontinuation Pathogenesis and modulation of inflammation [N4i 1] Tolerability Female Brief Reports Safety business Immunosuppressive Agents medicine.drug |
| Zdroj: | World Journal of Gastroenterology, 11, 35, pp. 5540-4 World Journal of Gastroenterology, 11(35), 5540-5544. Baishideng Publishing Group Inc World Journal of Gastroenterology, 11(35), 5540-5544. WJG Press De Boer, NK, Derijks, LJ, Gilissen, LP, Hommes, DW, Engels, LG, de Boer, S Y, den Hartog, G, Hooymans, PM, Makelburg, A B, Westerveld, B D, Naber, A H & Mulder, C J J 2005, ' On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprine or 6-mercaptopurine intolerant IBD patients ', World Journal of Gastroenterology, vol. 11, no. 35, pp. 5540-5544 . https://doi.org/10.3748/wjg.v11.i35.5540 Scopus-Elsevier World Journal of Gastroenterology, 11, 5540-4 |
| ISSN: | 1007-9327 |
| DOI: | 10.3748/wjg.v11.i35.5540 |
| Popis: | Contains fulltext : 49022.pdf (Publisher’s version ) (Open Access) AIM: To determine the tolerability and safety profile of a low-dose maintenance therapy with 6-TG in azathioprine (AZA) or 6-mercaptopurine (6-MP) intolerant inflammatory bowel disease (IBD) patients over a treatment period of at least 1 year. METHODS: Database analysis. RESULTS: Twenty out of ninety-five (21%) patients discontinued 6-TG (mean dose 24.6 mg; mean 6-TGN level 540 pmol/8 x 10(8) RBC) within 1 year. Reasons for discontinuation were GI complaints (31%), malaise (15%) and hepatotoxicity (15%). Hematological events occurred in three patients, one discontinued treatment. In the 6-TG-tolerant group, 9% (7/75) could be classified as hepatotoxicity. An abdominal ultrasound was performed in 54% of patients, one patient had splenomegaly. CONCLUSION: The majority of AZA or 6-MP-intolerant IBD patients (79%) is able to tolerate maintenance treatment with 6-TG (dosages between 0.3 and 0.4 mg/kg per d). 6-TG may still be considered as an escape maintenance immunosuppressant in this difficult to treat group of patients, taking into account potential toxicity and efficacy of other alternatives. The recently reported hepatotoxicity is worrisome and 6-TG should therefore be administered only in prospective trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|